Solid Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
SLDB$7.17+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2023 and 2022
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $74,015 | $155,384 |
| Available-for-sale securities | 49,625 | 58,338 |
| Prepaid expenses and other current assets | 6,094 | 5,916 |
| Total current assets | 129,734 | 219,638 |
| Operating lease, right-of-use asset | 26,539 | 28,949 |
| Property and equipment, net | 6,624 | 9,657 |
| Other non-current assets | 209 | 175 |
| Restricted cash | 1,833 | 1,833 |
| Total assets | $164,939 | $260,252 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,032 | $3,238 |
| Accrued expenses | 10,137 | 16,691 |
| Operating lease liabilities | 1,855 | 1,897 |
| Finance lease liabilities | 469 | 668 |
| Other current liabilities | 24 | 14 |
| Total current liabilities | 14,517 | 22,508 |
| Operating lease liabilities, excluding current portion | 22,707 | 24,279 |
| Finance lease obligations, excluding current portion | 1,234 | 1,703 |
| Other non-current liabilities | - | 96 |
| Total liabilities | 38,458 | 48,586 |
| Commitments and Contingencies (Note 12) | ||
| Stockholders’ Equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022; no shares issued and outstanding at December 31, 2023 and December 31, 2022 | — | — |
| Common stock, $0.001 par value; 60,000,000 shares authorized at December 31, 2023 and December 31, 2022; 20,386,606 shares issued and outstanding at December 31, 2023 and 19,556,732 shares issued and outstanding at December 31, 2022 | 20 | 20 |
| Additional paid-in capital | 785,199 | 774,452 |
| Accumulated other comprehensive income (loss) | 15 | (68) |
| Accumulated deficit | (658,753) | (562,738) |
| Total stockholders' equity | 126,481 | 211,666 |
| Total liabilities and stockholders' equity | $164,939 | $260,252 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.